期刊文献+

直肠癌MDT治疗

MDT Treatment of Rrectal Cancer
下载PDF
导出
摘要 直肠癌是我国常见的恶性肿瘤之一,传统的手术和术后化疗的临床治疗模式疗效并不理想。多学科综合治疗是直肠癌最佳治疗的模式,准确的直肠癌治疗前评估是直肠癌综合治疗方案实施的需要,个体化原则基础上进行的术前新辅助放化疗、术中规范化手术、术中腹腔内温热化疗和术后辅助放化疗等多学科合作的综合治疗,可明显改善了直肠癌的疗效。本文对此复习相关文献,对国内外直肠癌综合治疗进行综述。 Rectal cancer is one of the common malignant tumors in our country,the traditional operation and operation after clinical treatment model chemotherapeutic ef ect is not ideal.Multimodality treatment is the best treatment for rectal cancer,rectal cancer treatment of accurate assessment is needed before implementing the comprehensive treatment of rectal cancer program,the individual is based on the principle of preoperative neoadjuvant chemotherapy,surgery in treatment of operation,standard intraoperative hyperthermic chemotherapy and postoperative intraperitoneal chemotherapy and radiation of multi subject cooperation,can significantly improve the ef icacy of rectal cancer.This paper review the relevant literature at home and abroad,the comprehensive treatment of rectal cancer were reviewed.
作者 范增鹏 黄敬敏(综述) 张成武 王成(审校) FAN Zeng-peng;HUANG Jing-min;ZHANG Cheng-wu;WANG Cheng(Department of Gastrointestinal tumor surgery,Affiliated Hospital of Qinghai University,Xining 810000,Qinghai,China)
出处 《医学信息(医学与计算机应用)》 2014年第11期565-566,共2页 Medical Information
关键词 直肠癌 多学科 综合治疗 Rectal cancer Multidisciplinary Comprehensive treatment
  • 相关文献

参考文献3

二级参考文献74

  • 1廖盛日,戴莹,陈敏华,苏向前,顾晋.腔内超声对直肠癌术前分期诊断的应用价值[J].中国肿瘤临床,2005,32(4):200-203. 被引量:9
  • 2廖盛日,戴莹,范智慧,杨薇,吴薇,陈敏华.经直肠超声对直肠癌肠周淋巴结检出率分析[J].中国肿瘤临床,2006,33(19):1085-1087. 被引量:5
  • 3Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7:987-989
  • 4Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-147
  • 5Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase Ⅱ, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-65
  • 6Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342
  • 7Kopetz S, Glover KY, Eng C, Wolff RA, Chang DZ, Adinin RB, Morris J, Abbruzzese JL, Hoff PM. Phase Ⅱ study of infusional, 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) plus bevacizumab as first line treaterment for metastatic colorectal cancer. J Clin Oncol(Meeting Abstracts) 2007; 25: 18S Abst 4089
  • 8Sobrero AF, Young S, Belcewicz M, Young S, Balcewicz M, Chiarra S, Perez Carrion R, Mainwaring P, Gapski J, Clarke S, Langer B, Ackland S. Phase Ⅳ study of first line bevacizumab plus irinotecan and infusional 5-FU/LV in patients with metastatic colorectal cancer: AVIRI. J Clin Oncol(Meeting Abstracts) 2007; 25: 18S Abst 4068
  • 9Grothey A, Sugrue M, Hedrick E, D. Purdie D, Yi J,Dong W, Kozloff M. Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRITE). J Clin Oncol(Meeting Abstracts) 2007; 25: 18S Abst 4036
  • 10Kretzschmer A, Van Cutsem E, Micheal M, Rivera F, Berry S, DiBartolomeo M, Mazier M, Lutiger B, Cunningham D. Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and monotherapy for mCRC: First BEA Trial. J Clin Oncol(Meeting Abstracts) 2007; 25: 18S Abst 4072

共引文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部